Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment
Recruiting · NCT07807228 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are: Does the skin mycobiome change with treatment? Does the skin microbiome change with treatment? Does the abundance of Staphylococcus species change with treatment?
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults ≥18 years diagnosed with atopic dermatitis and initiating treatment with lebrikizumab
Exclusion criteria
- Previous treatment with lebrikizumab
- Current treatment with other biologics or JAK-inhibitors
- Hypersensitivity to lebrikizumab or any of its constituents
- Pregnancy or breastfeeding
- Active helminth infection
Where it is running
1 location listed.
- Dermatology Department Bispebjerg - Copenhagen, Denmark